Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis

BACKGROUND: This study evaluated the hemoglobin dose response, other efficacy measures and safety of daprodustat, an orally administered, hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anemia of chronic kidney disease. METHODS: Participants (n = 216) with baseline hemoglobi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Kidney J
Huvudupphovsmän: Meadowcroft, Amy M, Cizman, Borut, Holdstock, Louis, Biswas, Nandita, Johnson, Brendan M, Jones, Delyth, Nossuli, A Kaldun, Lepore, John J, Aarup, Michael, Cobitz, Alexander R
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2018
Ämnen:
Anemia
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6366140/
https://ncbi.nlm.nih.gov/pubmed/30746141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy014
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk